Shen Lian Biomedical(688098)2023-11-10 10:56Group 1: Company Overview and Technology - The company is engaged in the development of circular mRNA technology, which offers advantages such as high stability, long expression duration, and lower production costs compared to linear mRNA technology [1] - The company is building a GMP-level mRNA vaccine production line and is focusing on developing mRNA vaccines for major animal diseases such as porcine reproductive and respiratory syndrome and African swine fever [2] - The circular mRNA platform will enhance the speed of product development and diversify the product pipeline, positively impacting revenue and net profit [2] Group 2: Financial Performance - The company experienced a revenue decline of 8.32% in 2022 and 16.46% in the first three quarters of 2023, attributed to low market demand and policy impacts [3] - Despite the overall revenue decline, new product sales have shown growth, indicating a positive trend in product acceptance [3] Group 3: Product Development and Market Strategy - The company has established a comprehensive sales system, and new products are gradually penetrating the market, with a stable increase in large-scale farming clients [3] - The company is committed to continuous innovation and has developed various vaccine products, including inactivated vaccines for foot-and-mouth disease and diagnostic reagents [4] - The company is also exploring the development of chemical drugs, leveraging its advanced peptide synthesis technology [4] Group 4: Management and Future Plans - The management is focused on enhancing core competitiveness and aims to improve investor returns through better performance [4] - The company is open to increasing stock holdings by management if plans are established, indicating confidence in future growth [4]